Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Pluvia who wrote (319)	8/2/2005 4:53:40 PM
From: ddl	Read Replies (1) \| Respond to of 377

Pluvia you appear to be dancing around the questions. 1) Then the FDA could have considered this before PII protocol approval... I think it is something that was surely thought of, and if there were any questions as to the approval as a medical device, then I think VAS management would have some answering to do... I also feel the top cardios have done their DD, and would not be associated if this was the case. 2)Willforth being a past director for the medical division of the DFA has nothing to do with efficacy. He has everything to do with enssuring that the FDA applications have their i's dotted and t's crossed. 3)Yes, you can find Dr's that will say anything if paid enough... but do you really feel a group of THE TOP North American cardios would all be "whores"? 4) I would be shocked, if the FDA decided at the 11th hour to reclassify a device as a drug. I think it would reflect very poorly on the medical profession as a whole if such were to happen, considering who we have overseeing this whole process. Do you have any examples of this happening in the past? and I must say that on one of Vasogen PII trials, the results were very dramatic. You should re-read them. cheers btw... if you were invested in VAS, would you be long or short?